

Tam CS, Dimopoulos M, Garcia-Sanz R, et al. Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. *Blood Adv.* 2022;6(4):1296-1308.

Page 1300: In Table 3, under “Relative treatment intensity, median % (25th-75th percentile),” in column 1, row 3, “320 mg BID” should read “320 mg QD.” The error has been corrected in the published article.

DOI 10.1182/bloodadvances.2022008296

© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.